ABBV (AbbVie) Change In Receivables : $-570 Mil (TTM As of Mar. 2025)

View and export this data going back to 2012. Start your Free Trial

What is AbbVie Change In Receivables?

AbbVie's change in receivables for the quarter that ended in Mar. 2025 was $-1,479 Mil. It means AbbVie's Accounts Receivable increased by $1,479 Mil from Dec. 2024 to Mar. 2025 .

AbbVie's change in receivables for the fiscal year that ended in Dec. 2024 was $207 Mil. It means AbbVie's Accounts Receivable declined by $207 Mil from Dec. 2023 to Dec. 2024 .

AbbVie's Accounts Receivable for the quarter that ended in Mar. 2025 was $12,477 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. AbbVie's Days Sales Outstanding for the three months ended in Mar. 2025 was 85.33.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AbbVie's liquidation value for the three months ended in Mar. 2025 was $-117,906 Mil.

AbbVie Change In Receivables Historical Data

The historical data trend for AbbVie's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Change In Receivables Chart

AbbVie Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-929.00

-1,321.00

-1,455.00

66.00

207.00

AbbVie Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-702.00	178.00	344.00	387.00	-1,479.00

AbbVie Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-570 Mil.

AbbVie (NYSE:ABBV) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AbbVie's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	12477	/	13343	*	91
=	85.33

2. In Ben Graham's calculation of liquidation value, AbbVie's accounts receivable are only considered to be worth 75% of book value:

AbbVie's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5176	-	134703	+	0.75 * 12477	+	0.5 * 4526
=	-117,906

AbbVie Change In Receivables Related Terms

Thank you for viewing the detailed overview of AbbVie's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB:Germany ABBVCL:Chile ABBV:Canada ABBV34:Brazil ABBV:Austria ABBV:Argentina

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

https://www.abbvie.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Executives

Jeffrey Ryan Stewart	officer: SVP, US Commercial Operations	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents	officer: SVP, Chief Financial Officer	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee	officer: SVP, Controller	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Timothy J. Richmond	officer: EVP, Chief HR Officer	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis	officer: EVP, GC and Secretary	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Richard A Gonzalez	officer: Chairman of the Board and CEO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Nicholas Donoghoe	officer: SVP, Enterprise Innovation	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Robert A. Michael	officer: VP, Controller	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt	officer: SVP, Operations	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin	director	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis	director	1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Elaine K. Sorg	officer: Sr. V.P., U.S. Commercial Ops.	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom	officer: SVP & Pres Global Allerg Aesth	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin	director	200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Michael Severino	officer: EVP, R&D and CSO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064